Search results
Showing 8501 to 8550 of 8906 results
This evidence summary was produced at the start of the COVID-19 pandemic, when evidence was emerging. It has been withdrawn as the content is no longer relevant. See NICE's COVID-19 rapid guideline: managing COVID-19 for current guidance.
This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.
COVID-19 rapid evidence summary: vitamin D for COVID-19 (ES28)
This evidence summary has been updated and replaced by the COVID-19 rapid guideline on vitamin D (NG187).
COVID-19 rapid evidence summary: Tocilizumab for COVID-19 (ES33)
This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.
COVID-19 rapid evidence summary: Sarilumab for COVID-19 (ES34)
This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.
FebriDx for C-reactive protein and Myxovirus resistance protein A testing in primary care (MIB114)
This advice has been updated and replaced by NICE medtech innovation briefing 224.
Daylight for treating generalised anxiety disorder in adults (MIB309)
August 2023: This medtech innovation briefing (MIB) has been withdrawn at the company’s request as the evidence for the technology has moved on and the company expect to seek a NICE guidance output in due course.
Ventripoint Medical System Plus for measuring heart volume and function (MIB310)
February 2023: The medtech innovation briefing on Ventripoint Medical System Plus for measuring heart volume and function has been withdrawn as the company have withdrawn from the process.
QbTest for the assessment of attention deficit hyperactivity disorder (ADHD) (MIB318)
This advice has been updated and replaced by NICE healthtech guidance 729.
BPMpathway for rehabilitation support in joint replacement surgery (MIB319)
MIB319 BPMpathway for rehabilitation support in joint replacement surgery has been withdrawn. This is because factual inaccuracies have been identified. NHS England no longer fund NICE to produce or maintain medtech innovation briefings, therefore these are no longer being reviewed.
Flow transcranial direct current stimulation for treating depression (MIB324)
May 2024: This medtech innovation briefing has been withdrawn. This is because the evidence for the technology has changed since it was published. NHS England no longer funds NICE to produce or maintain medtech innovation briefings, so these are no longer being reviewed.
This advice has been updated and replaced by NICE medical technologies guidance 47.
AliveCor Heart Monitor and AliveECG app (Kardia Mobile) for detecting atrial fibrillation (MIB35)
This advice has been updated and replaced by NICE medtech innovation briefing 232.
The BCM – Body Composition Monitor for managing fluid in people having dialysis (MIB41)
This advice has been updated and replaced by NICE guidance HTG441
EndoPredict gene expression profiling assay for assessing risk of breast cancer recurrence (MIB44)
This advice has been updated and replaced by NICE diagnostics guidance 34.
PneuX for preventing ventilator-associated pneumonia in intensive care (MIB45)
This advice has been updated and replaced by NICE medical technologies guidance 48.
Elivaldogene autotemcel for treating cerebral adrenoleukodystrophy [ID1284]
Discontinued Reference number: GID-HST10038
Drisapersen for the first-line treatment of Duchenne's muscular dystrophy [ID911]
Discontinued Reference number: GID-HST10004
May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. See our guidance on treating severe asthma and our guideline on managing COVID-19.
COVID-19 rapid guideline: managing symptoms (including at the end of life) in the community (NG163)
This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.
27 May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COVID-19 see our guideline on managing COVID-19.
This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.
May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COPD see our guideline on diagnosing and managing COPD in over 16s and for people with COVID-19 see our guideline on managing COVID-19.
May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COVID-19 see our guideline on managing COVID-19.
This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.
May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with cystic fibrosis see our guideline on diagnosing and managing cystic fibrosis and for people with COVID-19 see our guideline on managing COVID-19.
May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COVID-19 see our guideline on managing COVID-19.
COVID-19 rapid guideline: delivery of systemic anticancer treatments (NG161)
September 2023: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COVID-19 see our guideline on managing COVID-19.
This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.
May 2022: This guidance has been withdrawn. For the latest guidance, see the UK Kidney Association’s recommendations for minimising the risk of transmission of COVID-19 in adult haemodialysis units. See also NICE's guideline on managing COVID-19.
This guidance has been updated and replaced by HealthTech guidance 639.
This guidance has been updated and replaced by NICE HealthTech guidance 643.
Pneumonia (community-acquired): antimicrobial prescribing (NG138)
This guideline has been updated and replaced by NICE's guideline on pneumonia in adults: diagnosis and management (NG250).
Suspected sepsis: recognition, diagnosis and early management (NG51)
This guideline has been updated and replaced by NICE's guidelines on suspected sepsis in people aged 16 or over (NG253), suspected sepsis in under 16s (NG254) and suspected sepsis in pregnant or recently pregnant people (NG255).
We have moved NG251 to become a 'NICE Review'. This is to better reflect what the purpose of this product is and to help you find relevant content more quickly. The review itself has not changed. See NICE review 1 on DMD Care UK’s guideline on cardiac care of children with dystrophinopathy and females carrying DMD-gene variations.
Pneumonia (hospital-acquired): antimicrobial prescribing (NG139)
This guideline has been updated and replaced by NICE's guideline on pneumonia: diagnosis and management (NG250).
This guideline has been updated and replaced by NICE guideline NG246.
This guideline has been updated and replaced by the NICE guideline on tobacco: preventing uptake, promoting quitting and treating dependence (NG209).
This guidance has been updated and replaced by NICE guideline NG203.
Asthma: diagnosis, monitoring and chronic asthma management (NG80)
This guideline has been updated and replaced by NICE guideline NG245.
TheraSphere for treating operable and inoperable hepatocellular carcinoma (MIB62)
This medtech innovation briefing has been updated and replaced by NICE technology appraisal guidance 688.
SIR-Spheres for treating inoperable hepatocellular carcinoma (MIB63)
This medtech innovation briefing has been updated and replaced by NICE technology appraisal guidance 688.
This medtech innovation briefing has been replaced by NICE healthtech guidance 716.
This medtech innovation briefing has been updated and replaced by NICE healthtech guidance 671.
This medtech innovation briefing has been updated and replaced by NICE's early value assessment guidance on Genedrive MT-RNR1 ID Kit for detecting a genetic variant to guide antibiotic use and prevent hearing loss in babies.
Artificial intelligence for analysing chest X-ray images (MIB292)
This medtech innovation briefing has been updated and replaced by HealthTech guidance 696.
This medtech innovation briefing (MIB) has been replaced by NICE healthtech guidance 715.
This advice has been updated and replaced by NICE healthtech guidance 616.
This advice has been updated and replaced by NICE healthtech guidance 601.
AnaConDa-S for sedation with volatile anaesthetics in intensive care (MIB229)
This advice has been updated and replaced by NICE healthtech guidance 607.